Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cressey

Showing results (41-50 of 160) with videos related to

Pageof 16
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
Open Forum Infectious Diseases|December 29, 2025
Oral Fluid Concentrations of Tenofovir and Emtricitabine for Monitoring HIV Antiretroviral Adherence: Findings From a Randomized Trial with Directly Observed Therapy (TARGET Study)Xin Niu, Tiancheng E Edwards, Jeannette A Dienhart, et al.
Therapeutic Drug Monitoring|January 15, 2011
Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavirTim R Cressey, Saik Urien, Deborah Hirt, et al.
Antimicrobial Agents and Chemotherapy|December 15, 2020
Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil FumarateAhizechukwu C Eke, Kensuke Shoji, Brookie M Best, et al.
JMIR Mhealth and Uhealth|April 22, 2022
A Mobile Phone App to Support Adherence to Daily HIV Pre-exposure Prophylaxis Engagement Among Young Men Who Have Sex With Men and Transgender Women Aged 15 to 19 Years in Thailand: Pilot Randomized Controlled TrialSurinda Kawichai, Wipaporn Natalie Songtaweesin, Prissana Wongharn, et al.
The Pediatric Infectious Disease Journal|August 1, 2019
Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed InfantsSuvaporn Anugulruengkitt, Piyarat Suntarattiwong, Pradthana Ounchanum, et al.
Infectious Diseases and Therapy|July 3, 2024
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1Hardik Chandasana, Sven C van Dijkman, Rashmi Mehta, et al.
Current HIV/AIDS Reports|July 7, 2020
Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and PreventionPaul K Drain, Ashley R Bardon, Jane M Simoni, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2023
Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trialSeef Abdalla, Alexandra Compagnucci, Yi Zheng, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2012
Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in ThailandFederica Fregonese, Intira J Collins, Gonzague Jourdain, et al.
Pageof 16

Showing results (41-50 of 160) with videos related to

Sort By:
Pageof 16
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
Open Forum Infectious Diseases|December 29, 2025
Oral Fluid Concentrations of Tenofovir and Emtricitabine for Monitoring HIV Antiretroviral Adherence: Findings From a Randomized Trial with Directly Observed Therapy (TARGET Study)Xin Niu, Tiancheng E Edwards, Jeannette A Dienhart, et al.
Therapeutic Drug Monitoring|January 15, 2011
Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavirTim R Cressey, Saik Urien, Deborah Hirt, et al.
Antimicrobial Agents and Chemotherapy|December 15, 2020
Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil FumarateAhizechukwu C Eke, Kensuke Shoji, Brookie M Best, et al.
JMIR Mhealth and Uhealth|April 22, 2022
A Mobile Phone App to Support Adherence to Daily HIV Pre-exposure Prophylaxis Engagement Among Young Men Who Have Sex With Men and Transgender Women Aged 15 to 19 Years in Thailand: Pilot Randomized Controlled TrialSurinda Kawichai, Wipaporn Natalie Songtaweesin, Prissana Wongharn, et al.
The Pediatric Infectious Disease Journal|August 1, 2019
Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed InfantsSuvaporn Anugulruengkitt, Piyarat Suntarattiwong, Pradthana Ounchanum, et al.
Infectious Diseases and Therapy|July 3, 2024
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1Hardik Chandasana, Sven C van Dijkman, Rashmi Mehta, et al.
Current HIV/AIDS Reports|July 7, 2020
Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and PreventionPaul K Drain, Ashley R Bardon, Jane M Simoni, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2023
Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trialSeef Abdalla, Alexandra Compagnucci, Yi Zheng, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2012
Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in ThailandFederica Fregonese, Intira J Collins, Gonzague Jourdain, et al.
Pageof 16